Cell line · CVCL_1453
Papers51
1 to 20 of 51
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| NK cell immune fitness stratifies small cell lung cancer into four functional states associated with clinical response. | J Liq Biopsy | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer. | Transl Lung Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Roles of Annexin A1 Expression in Small Cell Lung Cancer. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells. | Cancer Res Treat | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. | Genome Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Jumonji histone demethylases are therapeutic targets in small cell lung cancer. | Oncogene | 2024 | Cellosaurus cites it | PubMed | |
| Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CDK-independent role of D-type cyclins in regulating DNA mismatch repair. | Mol Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1453/papers